JNJ-26481585

• CAT Number: I005270
• CAS Number: 875320-29-9
• Molecular Formula: C₂₁H₂₆N₆O₂
• Molecular Weight: 394.21
• Purity: ≥95%
• Synonyms: N-hydroxy-2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxamide
• Target: HDAC
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IC50: 0.11 nM (HDAC1), 0.33 nM (HDAC2), 0.64 nM (HDAC4), 0.46 nM (HDAC10), 0.37 nM (HDAC11) [1]
• InChI: InChI=1S/C21H26N6O2/c1-26-14-17(18-4-2-3-5-19(18)26)11-22-10-15-6-8-27(9-7-15)21-23-12-16(13-24-21)20(28)25-29/h2-5,12-15,22,29H,6-11H2,1H3,(H,25,28)
• InChIKey: PAWIYAYFNXQGAP-UHFFFAOYSA-N
• SMILES: CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO

JNJ-26481585（Cat No.:I005270）is a potent histone deacetylase (HDAC) inhibitor with broad-spectrum activity against multiple HDAC isoforms. It exhibits significant anticancer potential by inducing cell cycle arrest, promoting apoptosis, and inhibiting tumor growth in various cancer models. By altering chromatin structure and gene expression, JNJ-26481585 modulates key pathways involved in cell proliferation and survival. Its ability to enhance the sensitivity of cancer cells to other treatments makes it a valuable compound for combination therapies. It is an essential tool for researchers exploring epigenetic cancer therapies.

Reference

[1]. Venugopal B, et al. A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors. Clin Cancer Res. 2013 Aug 1;19(15):4262-4272.
[2]. Carol H, et al. Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer. 2014 Feb;61(2):245-252.